133 related articles for article (PubMed ID: 8888658)
1. Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors.
Katz RJ; Hsia J; Walker P; Jacobs H; Kessler C
Am J Cardiol; 1996 Oct; 78(8):876-80. PubMed ID: 8888658
[TBL] [Abstract][Full Text] [Related]
2. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.
Koh KK; Mincemoyer R; Bui MN; Csako G; Pucino F; Guetta V; Waclawiw M; Cannon RO
N Engl J Med; 1997 Mar; 336(10):683-90. PubMed ID: 9041098
[TBL] [Abstract][Full Text] [Related]
3. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study.
Gebara OC; Mittleman MA; Sutherland P; Lipinska I; Matheney T; Xu P; Welty FK; Wilson PW; Levy D; Muller JE
Circulation; 1995 Apr; 91(7):1952-8. PubMed ID: 7895352
[TBL] [Abstract][Full Text] [Related]
4. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.
Brown NJ; Abbas A; Byrne D; Schoenhard JA; Vaughan DE
Circulation; 2002 Jan; 105(3):304-9. PubMed ID: 11804984
[TBL] [Abstract][Full Text] [Related]
6. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
7. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women.
Koh KK; Horne MK; Csako G; Waclawiw MA; Cannon RO
Am J Cardiol; 1999 Feb; 83(3):466-9, A10. PubMed ID: 10072247
[TBL] [Abstract][Full Text] [Related]
8. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy.
Nozaki M; Ogata R; Koera K; Hashimoto K; Nakano H
Climacteric; 1999 Jun; 2(2):124-30. PubMed ID: 11910665
[TBL] [Abstract][Full Text] [Related]
9. Circadian variation of fibrinolytic activity in blood.
Andreotti F; Kluft C
Chronobiol Int; 1991; 8(5):336-51. PubMed ID: 1818784
[TBL] [Abstract][Full Text] [Related]
10. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Shahar E; Folsom AR; Salomaa VV; Stinson VL; McGovern PG; Shimakawa T; Chambless LE; Wu KK
Circulation; 1996 Jun; 93(11):1970-5. PubMed ID: 8640970
[TBL] [Abstract][Full Text] [Related]
11. Effects of hormonal replacement therapy on lipid and haemostatic factors in post-menopausal ESRD patients.
Park JS; Jung HH; Yang WS; Kim SB; Min WK; Chi HS
Nephrol Dial Transplant; 2000 Nov; 15(11):1835-40. PubMed ID: 11071974
[TBL] [Abstract][Full Text] [Related]
12. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
Lindoff C; Peterson F; Lecander I; Martinsson G; Astedt B
Maturitas; 1996 May; 24(1-2):43-50. PubMed ID: 8794433
[TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.
Zunker P; Schick A; Padró T; Kienast J; Phillips A; Ringelstein EB
Neurol Res; 1999 Dec; 21(8):727-32. PubMed ID: 10596380
[TBL] [Abstract][Full Text] [Related]
14. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
Gallagher JC; Kable WT; Goldgar D
Am J Med; 1991 Feb; 90(2):171-8. PubMed ID: 1847582
[TBL] [Abstract][Full Text] [Related]
15. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
[TBL] [Abstract][Full Text] [Related]
16. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Brown NJ; Agirbasli MA; Williams GH; Litchfield WR; Vaughan DE
Hypertension; 1998 Dec; 32(6):965-71. PubMed ID: 9856958
[TBL] [Abstract][Full Text] [Related]
17. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency.
Devin JK; Blevins LS; Verity DK; Chen Q; Bloodworth JR; Covington J; Vaughan DE
J Clin Endocrinol Metab; 2007 Sep; 92(9):3633-9. PubMed ID: 17579195
[TBL] [Abstract][Full Text] [Related]
18. Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women.
Madsen JS; Kristensen SR; Gram J; Bladbjerg EM; Henriksen FL; Gram J; Christensen K; Jespersen J
J Thromb Haemost; 2003 Sep; 1(9):1984-91. PubMed ID: 12941041
[TBL] [Abstract][Full Text] [Related]
19. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
[TBL] [Abstract][Full Text] [Related]
20. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.
Vaughan DE; Rouleau JL; Ridker PM; Arnold JM; Menapace FJ; Pfeffer MA
Circulation; 1997 Jul; 96(2):442-7. PubMed ID: 9244210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
